A Prospective, Multicenter, Randomized, No-Treatment Controlled, Evaluator-Blinded, Superiority Clinical Trial to Evaluate the Efficacy and Safety of a Medical Collagen Filler for Correcting Infraorbital Depression
Infraorbital hollowing, also known as tear trough deformity, refers to a sunken groove extending from the medial canthal region along the infraorbital rim downward and laterally. It is one of the key features of facial aging and remains one of the most challenging issues in periorbital rejuvenation [1,2]. This deformity is particularly common among Asian populations, with approximately 60%-70% of middle-aged individuals presenting with varying degrees of infraorbital hollowing [2]; its incidence increases significantly with age. The formation of infraorbital hollowing results from the combined effects of multiple factors, including anatomical changes, soft tissue atrophy, skin aging, and impaired lymphatic circulation [2]. Beyond compromising facial aesthetics, it creates negative impressions of fatigue, aging, and sternness, which can severely affect patients' psychological well-being and social lives [3]. In recent years, driven by growing demand for facial rejuvenation, infraorbital hollowing correction has become a popular non-surgical aesthetic procedure.
However, due to the complex anatomy of the infraorbital region-characterized by thin skin, abundant vasculature, and fragile lymphatic drainage-traditional fillers are prone to issues such as migration, the Tyndall effect, and prolonged swelling, placing higher demands on both filling materials and injection techniques [4]. Collagen, as a natural biomaterial, offers distinct advantages for infraorbital hollowing correction owing to its excellent biocompatibility, low migration tendency, and light-scattering properties [5]. The mechanism of collagen injection for infraorbital hollowing correction is a complex, multi-stage, and multi-level process that achieves immediate physical volumization and tissue support. Injected collagen replenishes lost volume, forming a soft, cohesive fibrous structure that lifts the depressed area and restores a smooth transition between the lower eyelid and cheek, thereby reducing the hollowed appearance [5,6]. Meanwhile, due to its high adhesiveness, collagen binds loosened skin tissues together, repositions the disrupted fibrous scaffold network, and restores a youthful, firm contour [6]. After injection, the collagen gradually dehydrates and condenses, reorganizing into a fibrillar structure resembling native collagen in vivo, which further tightens tissues and enhances the supporting effect.
The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd. was approved for marketing by the NMPA in 2016 (Registration Certificate No.: Guo Xie Zhu Zhun 20163131609). It is indicated for dermal filling of the face to correct moderate to severe nasolabial folds, and has demonstrated favorable efficacy and safety in clinical practice. The proposed new indication is infraorbital filling for the improvement and correction of infraorbital hollowing. The objective of this study is to evaluate the efficacy and safety of this medical collagen filler manufactured by Feifan (Changchun) Medical Biotechnology Co., Ltd. in correcting the severity of infraorbital hollowing. In accordance with the Measures for the Administration of Medical Device Registration and Filing, the Good Clinical Practice for Medical Device Clinical Trials (GCP), and the Guidelines for Medical Device Clinical Trial Design, and adhering to the ethical principles of the World Medical Association Declaration of Helsinki, this study strives to maximize benefits for research participants while minimizing potential harm.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Hongqiang Li
- Numero di telefono: 0431-85085090
- Email: azhudezhuziyu@163.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Aged 18 years or older (based on the time of signing the informed consent form), of any gender; Assessed by the blinded investigator, both eyes must exhibit moderate to severe infraorbital hollowing (i.e., an Allergan Infraorbital Hollowing Scale [AIHS] grade of 2-3), and the participant must desire improvement in the infraorbital hollowing; Able to complete the efficacy self-assessment without wearing framed glasses (wearing contact lenses for self-assessment is acceptable); Able and willing to follow the investigator's instructions, comply with the treatment restrictions specified in this protocol, and attend all scheduled study visits; Voluntarily participating in this clinical trial and signing the research participant informed consent form.
Exclusion Criteria:
- 1. Known allergy to collagen, any component of the investigational product, or any local anesthetic (e.g., lidocaine or other amide-type anesthetics); 2. History of severe allergic reactions (e.g., anaphylactic shock, laryngeal edema, asthma, dyspnea, hypotension, syncope shortly after exposure to an allergen); 3. Presence of scars, deformities, unhealed wounds, or other conditions in the planned injection area and bilateral midface that may interfere with efficacy evaluation or increase treatment risk, potentially compromising visual assessment of the infraorbital rim, or active/recurrent inflammation or infection in either eye; 4. Previous treatment with any permanent filler (e.g., polymethylmethacrylate [PMMA], silicone, expanded polytetrafluoroethylene [ePTFE]), autologous fat, or unknown injectables in the planned injection area and bilateral midface; 5. Treatment with poly-L-lactic acid (PLLA), polycaprolactone (PCL), calcium hydroxylapatite (CaHA), or similar agents in the planned injection area and bilateral midface within 24 months prior to screening or planned during the trial period; 6. Treatment with cross-linked sodium hyaluronate, animal-derived collagen, or similar agents in the planned injection area and bilateral midface within 12 months prior to screening or planned during the trial period; 7. Treatment with recombinant human-like collagen, botulinum toxin, or similar agents in the planned injection area and bilateral midface within 6 months prior to screening or planned during the trial period; 8. History of active autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma, dermatomyositis); 9. Treatment with non-cross-linked sodium hyaluronate filler or cosmetic procedures (e.g., intense pulsed light [IPL], radiofrequency, dermabrasion, laser, chemical peels) in the planned injection area and bilateral midface within 6 months prior to screening; 10. Previous lower blepharoplasty or facial lift/brow lift within 12 months prior to screening; 11. In the investigator's judgment, presence of large lower eyelid fat pads affecting treatment or excessive pigmentation in the infraorbital area (excluding dark circles not caused by hyperpigmentation); 12. History of keloids or keloid-prone constitution (hypertrophic scarring tendency); 13. Chemotherapy, immunosuppressants, immunomodulatory therapy (e.g., monoclonal antibodies), or systemic corticosteroids (except inhaled corticosteroids) within 3 months prior to screening; 14. Screening liver function tests showing ALT and/or AST > 2 × upper limit of normal (ULN), or renal function tests showing Cr > 1.5 × ULN, and deemed by the investigator as unsuitable for the trial; 15. History of bleeding disorders (e.g., porphyria, coagulation factor deficiency, coagulopathy, or platelet disorders); clinically significant abnormal coagulation function at screening (e.g., APTT > 1.5 × ULN); or receipt of anticoagulant, antiplatelet, or thrombolytic therapy (e.g., warfarin, heparin, aspirin) within 2 weeks prior to screening; 16. In the investigator's judgment, severe dysfunction of vital organs (e.g., brain, heart, lung, liver, kidney), such as severe cardiovascular or cerebrovascular diseases (hospitalization for myocardial infarction or cardiac surgery, congestive heart failure, or myocardial infarction within 3 months; severe unstable arrhythmia; hypertrophic cardiomyopathy; severe aortic stenosis; aneurysm; stroke), severe pulmonary diseases (moderate to severe pneumonia, respiratory failure), or uncontrolled diabetes; 17. Epilepsy, mental disorders, or other severe neuropsychiatric conditions that may preclude completion of trial follow-up; 18. Lactating women or those planning pregnancy during the study period; 19. Participation in another interventional clinical trial within 1 month prior to screening; 20. Any other condition that, in the investigator's opinion, makes the participant unsuitable for this clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Varying degrees of Infraorbital Depression
|
The medical collagen filler developed by Feifan (Changchun) Medical Biotechnology Co., Ltd. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scores
Lasso di tempo: 3 months after the last injection in the experimental group and at 3 months after randomization in the control group
|
The effective rate of improvement in AIHS (Assessment of Infraorbital Hollowing Severity) scores at 3 months after the last injection in the experimental group and at 3 months after randomization in the control group, as evaluated by blinded investigator |
3 months after the last injection in the experimental group and at 3 months after randomization in the control group
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- FimanPharma-Xuanwu Hospital
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .